Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Join
FREE
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
Join
FREE
Pharma News, Views & Analysis
Filter
News
Articles
Podcasts
Infographics
Advertise With Us
Advertise With Us
FDA investigates trials sending US cells to foreign labs
The FDA has launched an immediate review of clinical trials involving the export of American patients’ living cells to China and other “hostile countries”.
Read more
VPAG hikes put UK life sciences at risk, warns pharma
The industry already contributes more than £17.6 billion directly to the UK economy, but it believes that growth has stagnated because of VPAG.
Pfizer completes exit from Haleon
Pfizer has announced plans to sell its remaining stake in Haleon plc, divesting approximately 662 million shares.
AstraZeneca buys EsoBiotec in $1bn cell therapy deal
AstraZeneca has announced a $1bn agreement to acquire EsoBiotec, a Belgian biotech firm pioneering in vivo cell therapies.
Daily pill for endometriosis to be offered by NHS
The NICE has approved the first daily oral treatment for endometriosis symptoms for use within the NHS in England.
Phase 2 trial begins for psychedelic-based depression treatment
A DMT-based treatment for people with treatment-resistant depression (TRD) has entered Phase 2 clinical trials.
UK Chikungunya vaccine approval in sight for Bavarian Nordic
The UK MHRA has validated Bavarian Nordics’ marketing authorisation application for its single-dose chikungunya vaccine.
Jazz Pharmaceuticals to acquire Chimerix in $935m deal
In a deal worth approximately $935m, Jazz Pharmaceuticals is set to acquire Chimerix, a biotechnology company developing oncology therapies.
Spotlight: February 2025
From a historic vaccine approval to a $50bn investment reshaping US drug manufacturing, February brought major pharma news to the fore.
Loading posts...
« Previous
1
…
4
5
6
7
8
…
29
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View